miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 28, 2026

Montrose Environmental Group Q4 Earnings Call Highlights

View original at finance.yahoo.com
Montrose Environmental Group Q4 Earnings Call Highlights Montrose Environmental Group logo Key Points Montrose reported a "record" 2025 with revenue of $830.5 million and consolidated adjusted EBITDA of $116.2 million, and set 2026 guidance of $840–$900 million in revenue and $125–$130 million in adjusted EBITDA (imply…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Organic growth of 12.7% exceeded long-term target of 7% to 9%

    80% confidence

  • Fourth-quarter revenue rose to $193.3 million from $189.1 million a year earlier

    80% confidence

  • Measurement and Analysis margins expected to remain elevated though modestly lower than 2025

    80% confidence

  • Quarterly margin decline attributed to lower margins in Measurement and Analysis and Remediation and Reuse, plus expenses tied to winding down renewables business

    80% confidence

  • M&A opportunities identified in testing and consulting across Australia, Canada, and the U.S.

    80% confidence

  • Water treatment total addressable market is more than $250 billion

    80% confidence

  • Company is targeting 60% operating cash conversion in 2026, above long-term 50%+ target

    80% confidence

  • Approximately 90% of Montrose's clients operate in private-sector industries and U.S. federal government exposure is less than 3% of revenue

    80% confidence

  • No M&A deals appear imminent in Q1 or early Q2, with potential bolt-on activity more likely in back half of 2026

    80% confidence

  • Remediation and Reuse margins expected to improve in 2026 as water treatment grows and operating leverage increases

    80% confidence

  • Recent U.S. EPA methane framework changes are not expected to have a material near-term impact on Montrose's services

    80% confidence

  • Company expects APR segment margins to strengthen in 2026 due to demand, pricing discipline, and operational efficiency

    80% confidence

  • 2025 was the strongest year in the company's history

    80% confidence

  • Montrose is a water technology business with opportunities broader than PFAS

    80% confidence

  • Company expects to generate approximately $180 million in cumulative operating cash flow across 2025 and 2026

    80% confidence

  • PFAS-related revenue remains about 10% to 15% of the business, with double-digit growth expected into 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Montrose Environmental Group Q4 Earnings Call Highlights — Source | Via News | es.VIA.NEWS